Results 71 to 80 of about 644,370 (183)

Potential role of aromatase inhibitors in the treatment of endometriosis

, 2014
Hatem Abu HashimDepartment of Obstetrics and Gynecology, Faculty of Medicine, Mansoura University, Mansoura, EgyptAbstract: Endometriosis is an estrogen-dependent chronic inflammatory disease affecting 5%–10% of reproductive-age women, with a ...
Abu Hashim H
core  

Dual Aromatase−Steroid Sulfatase Inhibitors

, 2016
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase−sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82
Christian Bubert (2225098), L. W. Lawrence Woo (2225101), Mary F. Mahon (1293876), Michael J. Reed (494088), Atul Purohit (1064), Oliver B. Sutcliffe (1283655), Surinder K. Chander (2312797), Andrew Smith (11197), Barry V. L. Potter (286876)   +8 more
core   +1 more source

Design, synthesis and biological evaluation of Exemestane derivatives as potent inhibitors of Aromatase

, 2019
Aromatase is a member of the cytochrome P450 superfamily, responsible for a key step in the biosynthesis of estrogens, allowing the aromatization of androgens into estrogens.
Alcaro S, Tavares da Silva EJ, Procopio AC, Lupia A, Costa G, Roleira FMF, Moraca F   +6 more
core  

Screening for Compounds with Aromatase Inhibiting Activities from Atractylodes macrocephala Koidz

Molecules, 2011
Ten compounds were isolated from the dichloromethane extract of Atractylodes macrocephala and their aromatase inhibiting activities were tested using an in vitro fluorescent-based aromatase assay.
Hai Jiang, Yuanyuan Li, Jing Shi
doaj   +1 more source

Long-term safety of aromatase inhibitors in the treatment of breast cancer

, 2008
Jean-Marc A NabholtzBreast Cancer Research Institute La Prandie, Valojoulx, FranceAbstract: Following promising data for metastatic breast cancer in terms of efficacy and safety profile, third-generation aromatase inhibitors (AI), anastrozole, letrozole,
Jean-Marc A Nabholtz
core  

Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors

Cancer Treatment and Research Communications
Breast cancer is a leading cause of death among women globally. Estrogen receptor (ER)-positive breast cancers account for ∼70 % of breast cancer diagnoses worldwide. Endocrine therapy is the primary treatment approach for ER-positive breast cancer.
Nayoung Kim, Kiven Erique Lukong
doaj   +1 more source

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Nature Communications, 2016
Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor ...
Pascal Gellert, Corrinne V. Segal, Qiong Gao, Elena López-Knowles, Lesley-Ann Martin, Andrew Dodson, Tiandao Li, Christopher A. Miller, Charles Lu, Elaine R. Mardis, Alexa Gillman, James Morden, Manuela Graf, Kally Sidhu, Abigail Evans, Michael Shere, Christopher Holcombe, Stuart A. McIntosh, Nigel Bundred, Anthony Skene, William Maxwell, John Robertson, Judith M. Bliss, Ian Smith, Mitch Dowsett, POETIC Trial Management Group and Trialists   +25 more
doaj   +1 more source

Aromatase inhibitors in post-menopausal endometriosis

Reproductive Biology and Endocrinology, 2011
Postmenopausal endometriosis is a rare clinical condition. The diagnosis and treatment of an endometriotic lesion in postmenopausal women is complicated.
Devroey Paul, Velasco Juan-Garcia, Kyrou Dimitra, Grimbizis Grigoris, Zavos Apostolos, Fatemi Human M, Polyzos Nikolaos P, Tarlatzis Basil, Papanikolaou Evangelos G   +8 more
doaj   +1 more source

Effect of letrozole on spermogram parameters and hormonal profile in infertile men: A clinical trial study

Endocrine Regulations, 2019
Objective. There is no reliable treatment for men with idiopathic infertility, but the relationship between severe sperm production and the ratio of estrogen to testosterone levels has been shown.
Peivandi Sepideh, Jafarpour Hamed, Abbaspour Mina, Ebadi Aghdas   +3 more
doaj   +1 more source

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer

Case Reports in Hematology, 2015
Aromatase inhibitors (AIs) are most commonly used for breast cancer patients with hormone receptor positive disease. Although the side effect profile of aromatase inhibitors is well known, including common side effects like arthralgia, bone pain ...
Sri Lakshmi Hyndavi Yeruva, Stanley Madu Nwabudike, Onyekachi Henry Ogbonna, Patricia Oneal   +3 more
doaj   +1 more source